找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Neuroendocrine Neoplasia Management; New Approaches for D Giordano Beretta,Alfredo Berruti,Orlando Goletti Book 2021 Springer Nature Switze

[復制鏈接]
樓主: Adams
21#
發(fā)表于 2025-3-25 04:23:09 | 只看該作者
New Concepts in Pathologyct of the tumor cells and their proliferative activity in terms of the number of mitoses or proliferation index (Ki-67)..In PanNENs, for example, Ki-67 labeling index correlates significantly with overall survival and also with disease progression in patients with advanced neoplasms and with tumor r
22#
發(fā)表于 2025-3-25 11:14:05 | 只看該作者
23#
發(fā)表于 2025-3-25 12:34:34 | 只看該作者
24#
發(fā)表于 2025-3-25 19:25:08 | 只看該作者
25#
發(fā)表于 2025-3-25 23:53:31 | 只看該作者
New Approaches in Medical Therapiesnhibitors (pazopanib, cabozantinib, lenvatinib, axitinib, surufatinib). Moreover, immune checkpoint inhibitors have also been investigated in NETs, with some encouraging results in well-differentiated tumors, especially for lung NETs. Clinical studies have also investigated the efficacy of epigeneti
26#
發(fā)表于 2025-3-26 02:36:37 | 只看該作者
Locoregional Therapies of NEN On the other hand, liver ablation, firstly introduced for percutaneous imaging-guided approach and more recently also applied in open and laparoscopic setting, can provide eradication of liver metastases with less invasiveness than traditional surgery. Moreover, due to the high rate of relapse afte
27#
發(fā)表于 2025-3-26 07:17:32 | 只看該作者
NETs of the Lungin receptors (SSTRs). Systemic chemotherapy is reserved for those cases of locally advanced or metastatic disease, even if the standard regimen has not yet been defined. The role of targeted therapies in LCs remains still limited with the exception of the only approved drug (everolimus) in clinical
28#
發(fā)表于 2025-3-26 11:13:44 | 只看該作者
29#
發(fā)表于 2025-3-26 13:38:54 | 只看該作者
Treatment of Pancreatic Neuroendocrine TumorsRRT) are all adequately supported by strong scientific data, and there are no clear criteria that favor the choice of one treatment over the other. The decision-making process should be conducted as part of a multidisciplinary tumor board and must be based on some key elements: the Grade (G 1,2,3),
30#
發(fā)表于 2025-3-26 19:44:08 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 06:23
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
客服| 东台市| 洛阳市| 布尔津县| 新巴尔虎右旗| 嘉黎县| 色达县| 邛崃市| 古交市| 淅川县| 巴中市| 仁化县| 瓦房店市| 万山特区| 应用必备| 顺平县| 定陶县| 伊川县| 张家港市| 微山县| 定远县| 农安县| 杭锦旗| 教育| 库车县| 威信县| 铜山县| 成安县| 岫岩| 重庆市| 滨州市| 衡水市| 抚州市| 浑源县| 泗洪县| 莱芜市| 巫溪县| 绥江县| 岫岩| 枣强县| 兰溪市|